{"id":"NCT03502616","sponsor":"Pfizer","briefTitle":"Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-07","primaryCompletion":"2019-12-19","completion":"2020-08-20","firstPosted":"2018-04-18","resultsPosted":"2021-01-11","lastUpdate":"2021-09-17"},"enrollment":270,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Tofacitinib","otherNames":[]}],"arms":[{"label":"Tofacitinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.","primaryOutcome":{"measure":"Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Tofacitinib","deltaMin":56.39,"sd":null},{"arm":"Placebo Then Tofacitinib","deltaMin":29.41,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":99,"countries":["United States","Australia","Bulgaria","Canada","China","Czechia","France","Hungary","Israel","Poland","Russia","South Korea","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["39695887","39671076","39636343","39320582","38825359","38790040","38696034","37909386","36138330","35654457","33906853"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=A3921120"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":133},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Arthralgia","Diarrhoea","Headache"]}}